Isavuconazole represents a novel generation of triazole antifungal agents for the treatment of invasive trichothecenes in adults. The pharmacokinetic profile of isavuconazole differs in special populations, including children, patients with extracorporeal membrane oxygenation, those with hepatic or renal injury, patients undergoing blood purification, and critically ill individuals and solid organ transplant recipients. These differences impact the safety and efficacy of patient treatment. This article presents the latest progress in the pharmacokinetic study of isavuconazole in these special populations.